Navigation Links
Bevacizumab found to improve survival for patients with advanced breast cancer
Date:12/26/2007

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy. The study, published in the December 27th issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.

Rush University Medical Center participated in the clinical trial which was sponsored by the National Cancer Institute and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).

The study of 722 women with recurrent (metastatic) breast cancer found that the women who received Avastin in combination with standard chemotherapy had a doubling of delay in worsening of their cancer by approximately five months, on average, compared to patients treated with chemotherapy alone. Those on Avastin had progression-free survival of 11.3 months compared to 6 months on standard chemotherapy alone.

"This therapy is a one-two punch! You hit the tumor with the chemo and sabotage new blood vessel growth by restricting its oxygen supply with Avastin," said Dr. Melody Cobleigh, co-author of the study and director of the Coleman Foundation Comprehensive Breast Center at Rush. "This is a noteworthy advance in cancer treatment."

Avastin is a therapeutic antibody designed to specifically inhibit vascular endothelial growth factor (VEGF), a protein that plays an important role in angiogenesis and the maintenance of existing blood vessels throughout the lifecycle of a tumor. By inhibiting VEGF, Avastin is designed to interfere with the blood supply to a tumor, which is thought to be critical to a tumors ability to grow and spread in the body.

Avastin not only slowed the growth of the tumor, it also doubled the remission rate (the shrinkage of tumors by 50 percent or more) compared with chemotherapy alone. With chemotherapy, 25% of tumors responded; with the combination of chemotherapy and bevacizumab, 49% did so.

Rush University Medical Center has been involved in the study of Avastin from the very beginning, participating in the Phase I, Phase II and Phase III studies of the drug. The next step is studying the drug in the adjuvant setting to determine if it can help decrease the risk of cancer recurrence.

"The tumor cant grow bigger than the size of a sesame seed without an oxygen supply," said Cobleigh. "And patients can stay on Avastin as long at it works. It is not a chemotherapy drug so it has minimal toxicity. "

According to the American Cancer Society, an estimated 178,000 women will be diagnosed with breast cancer and approximately 40,000 will die from the disease in the United States in 2007.


'/>"/>

Contact: Kim Waterman
Kimberly_Waterman@rush.edu
312-942-7820
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. One Species Genome Found Within Another
2. National Patient Safety Foundation Partners with Vocera Communications
3. R. P. Simmons Family Foundation Pledges $2 Million for New Childrens Hospital of Pittsburgh of UPMC Campus
4. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
5. AIDS Healthcare Foundation Applauds City Commissioners Support of Diversity, Urges Call for Mayors Resignation
6. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
7. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
8. The Tug McGraw Foundation Announces 2007 Fundraising Gala
9. The Arthur M. Blank Family Foundation Pushes for Pre-K Expansion in Georgia
10. Cipla, Tell the Truth; AIDS Healthcare Foundation Launches New Ad Campaign
11. Big Relief for Tiny Itch Mites Found in All Natural Spray Remedy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... 24, 2016 , ... Venture Construction Group (VCG) sponsors Luke’s Wings ... 20th at the Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. ... service members that have been wounded in battle and their families. Venture Construction Group ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: